Niagen Bioscience, Inc. — filing summary
Entity and period: The supplied filing is ChromaDex Corporation’s Form 10-K, not a filing under the name Niagen Bioscience, Inc. It covers the fiscal year ended December 28, 2013 (52 weeks), compared with the year ended December 29, 2012. It is an annual report, not a standalone fourth-quarter report; quarterly results are not clearly provided in the filing text.
Business context
ChromaDex supplied phytochemical reference standards, analytical and contract services, proprietary ingredients, and scientific and regulatory consulting through Spherix, acquired in December 2012. It sold its BluScience retail supplement product line to NeutriSci in March 2013. The company highlighted NIAGEN (nicotinamide riboside) and pTeroPure (pterostilbene) as proprietary ingredient opportunities, while noting that further development, clinical work, regulatory steps, and commercialization remained necessary.
Financial performance and liquidity
| Metric | FY 2013 | FY 2012 | Change or context |
|---|---|---|---|
| Net sales | $10.16 million | $11.61 million | Down 12% |
| Gross profit | $3.13 million | $2.28 million | Up 38% |
| Gross margin | 30.8% | 19.6% | Improved, principally on business mix and service utilization |
| Operating loss | $4.39 million | $11.64 million | Loss narrowed |
| Net loss | $4.42 million | $11.66 million | Loss narrowed 62% |
| Net loss per share | $0.04 | $0.13 | Basic and diluted |
| Cash used in operations | $3.91 million | $10.12 million | Operating cash burn continued |
| Cash from investing | $0.999 million | Cash used: $0.077 million | 2013 included $1.0 million from asset sales |
| Cash from financing | $4.65 million | $10.30 million | 2013 included stock issuance and warrant exercises |
| Cash at year-end | $2.26 million | $0.52 million | Up $1.74 million |
| Total assets | $8.99 million | $9.03 million | Nearly unchanged |
| Total liabilities | $3.32 million | $5.04 million | Down |
| Capital lease obligations | $0.42 million | $0.23 million | $0.14 million current; $0.28 million long-term |
Year-end current assets were $5.79 million and current liabilities were $2.84 million, implying working capital of about $2.95 million and a current ratio of about 2.0. Accounts payable fell to $1.44 million from $3.43 million; customer deposits rose to $0.55 million from $0.31 million. No material off-balance-sheet arrangements were reported other than operating leases. The filing does not identify material conventional borrowing beyond capital leases; the NeutriSci note was recorded as part of an investment in an affiliate.
Changes versus the prior year
- Sales declined primarily as the BluScience retail line was sold: retail segment net sales shifted from $3.08 million in 2012 to negative $60,285 in 2013, reflecting discounts, returns, and allowances. Core standards, contract services, and ingredients sales increased 7% to $9.07 million.
- Consulting sales were $1.15 million in 2013, versus $69,718 in 2012, which included only about one month following the Spherix acquisition.
- Sales and marketing expense fell 57% to $2.36 million, mainly because the prior year included a national BluScience advertising campaign. General and administrative expense fell 39% to $5.12 million, including lower share-based compensation, investor-relations costs, and severance costs.
- Inventory fell to $2.20 million from $5.21 million, mainly following the BluScience sale. Despite lower net sales, gross profit increased as service utilization and fixed-cost coverage improved.
- The company raised $3.0 million gross through a 2013 common-stock sale at $0.85 per share and received additional proceeds from warrant and option exercises.
Outlook, commentary, risks, and unusual items
- Management said that, with expense curtailment, existing cash and expected operating cash generation were projected to fund the operating plan through March 2015. Additional financing could be needed; no commitment was in place, and financing might be unavailable or dilutive. Management warned that insufficient funding could delay or end expansion plans.
- Plans included increased research and development, expanded service capacity, a larger chemical library program, and collaboration on a GMP-compliant pilot plant. These were plans, not assured outcomes. The company also described an OPKO Latin America licensing arrangement, but reported no transactions under it as of year-end.
- Following year-end, ChromaDex assigned the NeutriSci senior secured convertible note, with $2.275 million outstanding, for a stated $1.25 million. It reported net proceeds of $1.0925 million after fees and legal costs, and agreed to transfer NeutriSci preferred shares valued at $500,000 to the buyer and $50,000 to the placement agent upon specified future events. The assignment had no recourse to ChromaDex.
- The BluScience sale accounting was revised: because the fair value and collectability of non-cash consideration could not be reliably determined, the company applied the cost-recovery method and would not recognize a gain until its cost basis was recovered. Prior interim statements were restated; the filing says the amendments were non-cash.
- Management identified a material weakness in internal control over financial reporting related to accounting for asset sales involving non-cash consideration and equity-method investments. Disclosure controls and internal control over financial reporting were deemed ineffective at year-end; remediation was in progress. The external auditor did not attest to internal controls.
- Principal risks include continuing losses and cash needs; uncertain market acceptance and commercialization of ingredients; clinical, regulatory, and product-liability exposure; competition; reliance on suppliers, including overseas sources; protection and enforcement of intellectual property; and the thinly traded OTC market and potential shareholder dilution. The company reported no legal proceedings believed likely to have a material adverse effect.
Most important facts for investors to verify
- Whether operating cash burn and losses improved sustainably, and whether financing or expense reductions were required after the stated March 2015 runway estimate.
- Collections, recoverability, and remaining economic exposure relating to the NeutriSci note, preferred shares, and BluScience sale; confirm the accounting effects of the subsequent assignment.
- Progress and evidence supporting NIAGEN and pTeroPure commercialization, including clinical results, regulatory status, manufacturing capacity, and customer demand.
- Whether the disclosed material weakness was fully remediated and whether later filings reported effective financial-reporting controls.
- Potential dilution: 13.16 million options were outstanding at year-end at a weighted-average exercise price of $1.08, in addition to subsequent equity awards and any later capital raises.